Cantor Fitzgerald set a $103.00 target price on Spark Therapeutics (NASDAQ:ONCE) in a report released on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently issued reports on ONCE. Credit Suisse Group boosted their price objective on shares of Spark Therapeutics from $75.00 to $98.00 and gave the company an outperform rating in a report on Monday, July 9th. BMO Capital Markets boosted their price objective on shares of Spark Therapeutics from $78.00 to $98.00 and gave the company an outperform rating in a report on Monday, June 25th. ValuEngine upgraded shares of Spark Therapeutics from a buy rating to a strong-buy rating in a report on Tuesday, June 26th. Royal Bank of Canada cut shares of Spark Therapeutics from an outperform rating to a sector perform rating and set a $100.00 price objective for the company. in a report on Thursday, July 19th. Finally, B. Riley began coverage on shares of Spark Therapeutics in a report on Thursday, June 28th. They set a neutral rating and a $74.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. Spark Therapeutics has an average rating of Hold and a consensus price target of $72.15.

Shares of NASDAQ ONCE opened at $55.55 on Friday. The company has a market cap of $2.09 billion, a P/E ratio of -7.28 and a beta of 2.22. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.34). The firm had revenue of $25.19 million for the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative net margin of 185.46% and a negative return on equity of 17.33%. equities analysts forecast that Spark Therapeutics will post -1.66 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank boosted its holdings in shares of Spark Therapeutics by 6.4% in the first quarter. Swiss National Bank now owns 54,700 shares of the biotechnology company’s stock valued at $3,642,000 after buying an additional 3,300 shares during the period. Partner Investment Management L.P. boosted its holdings in Spark Therapeutics by 27.9% during the second quarter. Partner Investment Management L.P. now owns 11,511 shares of the biotechnology company’s stock worth $953,000 after purchasing an additional 2,513 shares during the last quarter. State of Wisconsin Investment Board boosted its holdings in Spark Therapeutics by 21.9% during the second quarter. State of Wisconsin Investment Board now owns 32,300 shares of the biotechnology company’s stock worth $2,673,000 after purchasing an additional 5,800 shares during the last quarter. Amalgamated Bank boosted its holdings in Spark Therapeutics by 29.7% during the second quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Pinnacle Associates Ltd. acquired a new position in Spark Therapeutics during the first quarter worth $15,611,000.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

See Also: Should You Consider an Index Fund?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.